Meridia

sibutramine

A central, appetite-suppressing agent that blocks reuptake of serotonin, norepinephrine and, to a lesser extent, dopamine; it provides a sensation of fullness from lesser amounts of food, and increases metabolism. Sibutramine was approved for use as a dietary adjunct in the mid-1990s and was heavily marketed until 2010, when it was withdrawn from the market due to the increased risk of cardiovascular events and strokes associated with its use. Sibutramine is a Schedule-IV Controlled Substance.

IndicationsObese patients with an initial BMI of ≥ 30 kg/m2 or ≥ 27 kg/m2 in addition to other factors (e.g., hypertension, diabetes, dyslipidemia).

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.